A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Phase 2 Withdrawn
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Phase 1 Withdrawn
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
Phase 1 Withdrawn
CheckMate 79X
Phase 1/2 Withdrawn
SALIENT
Phase 2 Withdrawn
CERAD-IMMUNE
Phase 2 Withdrawn
Yervoy Pregnancy Surveillance Study
Withdrawn
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Phase 2 Withdrawn
CINDI
Phase 1/2 Withdrawn
CheckMate 7UA
Phase 2 Withdrawn
BENEFIT
Phase 1 Withdrawn
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Phase 2 Withdrawn
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Phase 2 Withdrawn
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Phase 2 Withdrawn
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Phase 2 Withdrawn
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Phase 1/2 Withdrawn
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase 1/2 Withdrawn
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Phase 2 Withdrawn
CheckMate 955
Phase 3 Withdrawn
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
Phase 1 Withdrawn
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
Phase 1 Withdrawn
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Phase 1 Withdrawn
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Phase 1/2 Withdrawn
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
Phase 2 Withdrawn
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Phase 1/2 Withdrawn
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Phase 2 Withdrawn
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
Phase 1/2 Withdrawn
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Phase 1 Withdrawn